Literature DB >> 23128964

The reproducibility of bolus allergen challenges; power calculations for clinical trials.

Raminder Aul, Hayley King, Umme Kolsum, Dave Singh.   

Abstract

Mesh：

Substances：

Year:  2012        PMID： 23128964     DOI： 10.1007/s00228-012-1442-z

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  9 in total

1.  Repeatability of allergen-induced airway inflammation.

Authors:  G M Gauvreau; R M Watson; T J Rerecich; E Baswick; M D Inman; P M O'Byrne
Journal:  J Allergy Clin Immunol       Date:  1999-07       Impact factor: 10.793

2.  Comparison of incremental and bolus dose inhaled allergen challenge in asthmatic patients.

Authors:  D A Taylor; J G Harris; B J O'Connor
Journal:  Clin Exp Allergy       Date:  2000-01       Impact factor: 5.018

3.  Reproducibility of allergen-induced early and late asthmatic responses.

Authors:  M D Inman; R Watson; D W Cockcroft; B J Wong; F E Hargreave; P M O'Byrne
Journal:  J Allergy Clin Immunol       Date:  1995-06       Impact factor: 10.793

4.  Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma.

Authors:  D J Evans; P J Barnes; S M Spaethe; E L van Alstyne; M I Mitchell; B J O'Connor
Journal:  Thorax       Date:  1996-12       Impact factor: 9.139

5.  Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma.

Authors:  Dave Singh; Duncan Richards; Richard G Knowles; Sheila Schwartz; Ashley Woodcock; Steve Langley; Brian J O'Connor
Journal:  Am J Respir Crit Care Med       Date:  2007-08-23       Impact factor: 21.405

6.  Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies.

Authors:  Sally Wenzel; Darren Wilbraham; Rick Fuller; Elise Burmeister Getz; Malinda Longphre
Journal:  Lancet       Date:  2007-10-20       Impact factor: 79.321

7.  The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma.

Authors:  Dave Singh; Frank Petavy; Alex J Macdonald; Aili L Lazaar; Brian J O'Connor
Journal:  Respir Res       Date:  2010-03-01

8.  Increases in activated T lymphocytes, eosinophils, and cytokine mRNA expression for interleukin-5 and granulocyte/macrophage colony-stimulating factor in bronchial biopsies after allergen inhalation challenge in atopic asthmatics.

Authors:  A M Bentley; Q Meng; D S Robinson; Q Hamid; A B Kay; S R Durham
Journal:  Am J Respir Cell Mol Biol       Date:  1993-01       Impact factor: 6.914

Review 9.  Allergen inhalation challenge: a human model of asthma exacerbation.

Authors:  Gail M Gauvreau; Michelle Y Evans
Journal:  Contrib Microbiol       Date:  2007
  9 in total
  1 in total

1.  High- and low-dose allergen challenges in asthmatic patients using inhaled corticosteroids.

Authors:  Wha-Yong Lee; Thomas Southworth; Steven Booth; Dave Singh
Journal:  Br J Clin Pharmacol       Date:  2015-03       Impact factor: 4.335
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.